{"abstract":"The National Cancer Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to PreciThera, Inc, located in Montreal, Canada.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/08/05/2020-17098.html","cfr_references":[],"citation":"85 FR 47394","comment_url":null,"comments_close_on":"2020-08-20","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 20, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-17098","effective_on":null,"end_page":47394,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/08/05/2020-17098.xml","html_url":"https://www.federalregister.gov/documents/2020/08/05/2020-17098/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-therapies-to","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-17098?publication_date=2020-08-05","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-08-05/2020-17098/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":144,"last_updated":"2026-06-27 00:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-08-05/pdf/2020-17098.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-17098.pdf?1596545141","publication_date":"2020-08-05","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/08/05/2020-17098.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:51:45Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":47394,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development and Commercialization of Therapies To Treat IGF-1 Deficiency and Achondroplasia","toc_doc":"Development and Commercialization of Therapies to Treat IGF1 Deficiency and Achondroplasia","toc_subject":"Prospective Grant of Exclusive Patent License:\n","topics":[],"type":"Notice","volume":85}